While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...